Management of coronary artery perforation in patients receiving abciximab.
Del Campo
C
C
Zelman
R
R
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003327:Coronary Disease / Q000628:therapy*; D003331:Coronary Vessels / Q000293:injuries*; D004621:Embolization, Therapeutic; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab